Showing results (11-20 of 100) with videos related to
Sort By:
Pageof 10
Anti-Cancer Drugs|June 4, 2011
An in-vitro evaluation of the polo-like kinase inhibitor GW843682X against paediatric malignanciesKristina Spaniol, Joachim Boos, Claudia Lanvers-KaminskyCancer Chemotherapy and Pharmacology|February 28, 2002
Peak plasma concentrations of doxorubicin in children with acute lymphoblastic leukemia or non-Hodgkin lymphomaGeorg Hempel, Silke Flege, Gudrun Würthwein, et al.Medical and Pediatric Oncology|October 12, 2002
On the origin of EEG-slowing and encephalopathy during induction treatment of acute lymphoblastic leukemiaRudolf Korinthenberg, Bernadette Scheuring, Joachim Boos, et al.Onkologie|February 25, 2011
Carboplatin dosing in children: calculation by different formulaeGudrun Würthwein, Barbara Krefeld, Joachim Gerss, et al.Journal of Chromatography. A|December 25, 2002
Determination of free and liposome-associated daunorubicin and daunorubicinol in plasma by capillary electrophoresisNina Griese, Gottfried Blaschke, Joachim Boos, et al.British Journal of Clinical Pharmacology|September 13, 2003
Population pharmacokinetics of liposomal daunorubicin in childrenGeorg Hempel, Dirk Reinhardt, Ursula Creutzig, et al.European Journal of Clinical Pharmacology|May 10, 2014
Population pharmacokinetics of intravenous busulfan in children: revised body weight-dependent NONMEM® model to optimize dosingChristian Diestelhorst, Joachim Boos, Jeannine S McCune, et al.Cancer Chemotherapy and Pharmacology|August 13, 2002
c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571)Marc Hotfilder, Claudia Lanvers, Heribert Jürgens, et al.Pediatric Blood & Cancer|September 11, 2009
Physical activity and childhood cancerCorinna Winter, Carsten Müller, Christiane Hoffmann, et al.Pediatric Blood & Cancer|December 21, 2013
Comparison of self-reported physical activity in children and adolescents before and during cancer treatmentMiriam Götte, Sabine Kesting, Corinna Winter, et al.Pageof 10